Overview

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the effects of telaglenastat on cardiac repolarization (relative to placebo) in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Calithera Biosciences, Inc